Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPCA) previously treated with docetaxel-based chemotherapy. - Ohlmann,C.H.; Engelmann,U.; Heidenreich,A. (Prostate Cancer Symposium, 2006)